Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

40.14 -0.08 (-0.20%)
Streaming Delayed Price Updated: 11:48 AM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,962,839
Open 40.20
Bid (Size) 40.13 (35)
Ask (Size) 40.14 (7)
Prev. Close 40.22
Today's Range 39.99 - 40.30
52wk Range 39.23 - 56.32
Shares Outstanding 5,606,688,356
Dividend Yield 3.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Bear of the Day: BioNTech
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines. 
Via Talk Markets
2 Dividend Stocks Down 11% to 22% to Buy and Hold Forever
Investors should buy the dips on these healthcare giants. 
Via The Motley Fool

Performance

YTD
-21.69%
-21.69%
1 Month
-1.57%
-1.57%
3 Month
-21.49%
-21.49%
6 Month
-8.42%
-8.42%
1 Year
-24.66%
-24.66%

More News

Read More
This entertainer is taking her shot at some new things — and doesn’t want pneumococcal pneumonia to stand in her way
Via Brandpoint
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer
Via Benzinga
Bear of the Day: Pfizer Inc.
Via Talk Markets
2 Rock Solid Dividend Stocks to Buy on the Dip
Via The Motley Fool
Can This New Drug Boost Pfizer's Stock?
Via The Motley Fool
Check Out What Whales Are Doing With PFE
Via Benzinga
BioNTech Is Ripe For A Rebound In 2023
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion
Via Investor's Business Daily
3 Low P/E Stocks That Are Bound to Rebound This Year
Via InvestorPlace
Could CRISPR Therapeutics Become the Next Moderna?
Via The Motley Fool
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
Via The Motley Fool
3 Healthcare Spinoffs Worth a Look, But 1 Has the Best Long-Term Potential
Via The Motley Fool
This Cancer Drug Candidate Could Be a Hit for Pfizer
Via The Motley Fool
I Own 12 High-Yield Dividend Stocks. Here's the Best of the Bunch.
Via The Motley Fool
7 Blue-Chip Stocks to Buy for Capital Preservation
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval
Via Benzinga
Why Pfizer Likely Isn't Done With M&A After the Seagen Deal
Via The Motley Fool
China's First mRNA Vaccine: Drugmaker CSPC Wins China's Approval For COVID-19 Vaccine
Via Benzinga
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via TheNewswire.com
Exposures Product Safety
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
Via News Direct
Exposures Product Safety
3 Dividend Contenders to Buy Now for Long-Term Gains Later
Via MarketBeat
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.